Antibody escape and global spread of SARS-CoV-2 lineage A.27

SARS-CoV-2 A.27 株的抗体逃逸和全球传播

阅读:5
作者:Tamara Kaleta # ,Lisa Kern # ,Samuel Leandro Hong # ,Martin Hölzer ,Georg Kochs ,Julius Beer ,Daniel Schnepf ,Martin Schwemmle ,Nena Bollen ,Philipp Kolb ,Magdalena Huber ,Svenja Ulferts ,Sebastian Weigang ,Gytis Dudas ,Alice Wittig ,Lena Jaki ,Abdou Padane ,Adamou Lagare ,Mounerou Salou ,Egon Anderson Ozer ,Ndodo Nnaemeka ,John Kofi Odoom ,Robert Rutayisire ,Alia Benkahla ,Chantal Akoua-Koffi ,Abdoul-Salam Ouedraogo ,Etienne Simon-Lorière ,Vincent Enouf ,Stefan Kröger ,Sébastien Calvignac-Spencer ,Guy Baele ,Marcus Panning ,Jonas Fuchs

Abstract

In spring 2021, an increasing number of infections was observed caused by the hitherto rarely described SARS-CoV-2 variant A.27 in south-west Germany. From December 2020 to June 2021 this lineage has been detected in 31 countries. Phylogeographic analyses of A.27 sequences obtained from national and international databases reveal a global spread of this lineage through multiple introductions from its inferred origin in Western Africa. Variant A.27 is characterized by a mutational pattern in the spike gene that includes the L18F, L452R and N501Y spike amino acid substitutions found in various variants of concern but lacks the globally dominant D614G. Neutralization assays demonstrate an escape of A.27 from convalescent and vaccine-elicited antibody-mediated immunity. Moreover, the therapeutic monoclonal antibody Bamlanivimab and partially the REGN-COV2 cocktail fail to block infection by A.27. Our data emphasize the need for continued global monitoring of novel lineages because of the independent evolution of new escape mutations.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。